Want to join the conversation?
$CAH's operating earnings for 3Q16 increased by 11% and non-GAAP operating earnings grew by 20%. The increases were due to sales growth from existing and new pharmaceutical distribution customers, performance under its Pharmaceutical segment generics program, and acquisitions, offset in part by the adverse impact of customer pricing changes.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)